- Recruiting
NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies
Updated: May 25, 2022
FT538
induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538

NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Sponsor
ClinicalTrials.gov Identifier: NCT04614636
Official Title: A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
First Posted : November 4, 2020
Click here for details on ClinicalTrials.gov
iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 (Code C176623)
FT 538
FT-538
FT538
induced pluri